Pacira BioSciences posted $726.4 million in total revenue for 2025 — a record — yet a small activist, DOMA Perpetual Capital Management, is still pushing to replace three board seats at the June 9 annual meeting. That disconnect is the story. A company with 79.4% GAAP gross margins and EXPAREL volume growth accelerating from 3.6% to 6.2% year-over-year does not fit the profile of a board in need of activist rescue. DOMA’s contest looks less like a value-creation thesis and more like a timing opportunist swinging at a stock that has already moved — up 31% since the 5×30 strategy launched — without credit for the turn.
The substance of Pacira’s defense rests on three pillars, and two of them are genuinely durable. First, the EXPAREL IP settlement with Fresenius Kabi locks in exclusivity through 2030 with a capped generic transition extending to 2039. That structure eliminates the cliff risk that typically devastates single-asset specialty pharma valuations and buys the management team a defined window to execute diversification. Second, the J&J MedTech and LG Chem partnerships have tripled U.S. physician reach — a commercial infrastructure expansion that Pacira could not have funded organically without dilution. The third pillar, the pipeline, is the most speculative: PCRX-201, a locally administered gene therapy for osteoarthritis, and PCRX-2002, an in-licensed long-acting ropivacaine formulation, are both Phase 2 assets with no efficacy data yet public.
DOMA’s core argument — that the board failed to maximize EXPAREL’s value during its exclusivity window — lands harder than Pacira admits. GAAP net income of $7 million on $726 million in revenue is a thin margin for a company with 81% non-GAAP gross margins. The gap between gross and net reflects a cost structure that hasn’t been rationalized as aggressively as the revenue line suggests it should be. That’s a legitimate governance critique, and Pacira’s proxy defense addresses it obliquely at best. CEO Frank Lee’s appointment in 2024 is positioned as the inflection, but 16 months is a short track record on which to anchor a long-term capital allocation thesis.
The real test arrives at year-end: Pacira has committed to three pipeline data readouts before December 31. If PCRX-201 osteoarthritis data shows any meaningful symptom or structural signal, the 5×30 narrative gains independent validation beyond revenue metrics. A clean miss there transforms the 2030 diversification story into an EXPAREL extension play dressed in pipeline language — and gives DOMA’s successor activists a much sharper weapon than the current proxy fight provides.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
